Good Works II (GWII) to Combine with Direct Biologics in $723M Deal

Good Works II (NASDAQ:GWII) has entered into a definitive agreement to combine with drug developer Direct Biologics at an enterprise value of $723 million. Austin, Texas-based Direct Biologics is developing anti-inflammatory treatments aimed at accelerating recovery from COVID-19 infection and other respiratory and inflammation-related ailments. The combined company is expected to trade on the Nasdaq
Read More